Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

OVERALL SURVIVAL RANGED FROM TWO TO TWENTY TWO MONTHS

The success of ridaforolimus in extending progression-free survival was already known, but updated data show that patients are likely to live longer when taking the drug. Although the follow-up in the study is continuing, it showed a survival benefit of more than two months to about 22 months, as of the data cut-off in the fall. Merck is conducting an analysis, and an update to the survival data will be presented at the June meeting, an Ariad spokeswoman said